Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200327520> ?p ?o ?g. }
- W4200327520 endingPage "355" @default.
- W4200327520 startingPage "345" @default.
- W4200327520 abstract "Patients with triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy (NAC) have high risk of recurrence with prior data suggesting improved outcomes with capecitabine. Targeted agents have demonstrated activity across multiple cancer types. BRE12-158 was a phase II, multicenter trial that randomly allocated patients with TNBC with residual disease after NAC to genomically directed therapy versus treatment of physician choice (TPC).From March 2014 to December 2018, 193 patients were enrolled. Residual tumors were sequenced using a next-generation sequencing test. A molecular tumor board adjudicated all results. Patients were randomly allocated to four cycles of genomically directed therapy (arm A) versus TPC (arm B). Patients without a target were assigned to arm B. Primary end point was 2-year disease-free survival (DFS) among randomly assigned patients. Secondary/exploratory end points included distant disease-free survival, overall survival, toxicity assessment, time-based evolution of therapy, and drug-specific outcomes.One hundred ninety-three patients were randomly allocated or were assigned to arm B. The estimated 2-year DFS for the randomized population only was 56.6% (95% CI, 0.45 to 0.70) for arm A versus 62.4% (95% CI, 0.52 to 0.75) for arm B. No difference was seen in DFS, distant disease-free survival, or overall survival for the entire or randomized populations. There was increased uptake of capecitabine for TPC over time. Patients randomly allocated later had less distant recurrences. Circulating tumor DNA status remained a significant predictor of outcome with some patients demonstrating clearance with postneoadjuvant therapy.Genomically directed therapy was not superior to TPC for patients with residual TNBC after NAC. Capecitabine should remain the standard of care; however, the activity of other agents in this setting provides rationale for testing optimal combinations to improve outcomes. Circulating tumor DNA should be considered a standard covariate for trials in this setting." @default.
- W4200327520 created "2021-12-31" @default.
- W4200327520 creator A5000862048 @default.
- W4200327520 creator A5002316061 @default.
- W4200327520 creator A5003348942 @default.
- W4200327520 creator A5005007467 @default.
- W4200327520 creator A5006346528 @default.
- W4200327520 creator A5009816526 @default.
- W4200327520 creator A5010925062 @default.
- W4200327520 creator A5015980183 @default.
- W4200327520 creator A5018790034 @default.
- W4200327520 creator A5018890673 @default.
- W4200327520 creator A5020251022 @default.
- W4200327520 creator A5029357210 @default.
- W4200327520 creator A5032268177 @default.
- W4200327520 creator A5033046698 @default.
- W4200327520 creator A5035803024 @default.
- W4200327520 creator A5036380555 @default.
- W4200327520 creator A5046488005 @default.
- W4200327520 creator A5049097819 @default.
- W4200327520 creator A5049263574 @default.
- W4200327520 creator A5051674135 @default.
- W4200327520 creator A5053390874 @default.
- W4200327520 creator A5064024878 @default.
- W4200327520 creator A5064891388 @default.
- W4200327520 creator A5066442050 @default.
- W4200327520 creator A5068100422 @default.
- W4200327520 creator A5068480776 @default.
- W4200327520 creator A5068666503 @default.
- W4200327520 creator A5071176191 @default.
- W4200327520 creator A5073577602 @default.
- W4200327520 creator A5075046330 @default.
- W4200327520 creator A5079711212 @default.
- W4200327520 creator A5085329460 @default.
- W4200327520 creator A5088081245 @default.
- W4200327520 date "2022-02-01" @default.
- W4200327520 modified "2023-09-23" @default.
- W4200327520 title "BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer" @default.
- W4200327520 cites W1955397179 @default.
- W4200327520 cites W2014436580 @default.
- W4200327520 cites W2075894019 @default.
- W4200327520 cites W2122433511 @default.
- W4200327520 cites W2134203864 @default.
- W4200327520 cites W2147415463 @default.
- W4200327520 cites W2151824850 @default.
- W4200327520 cites W2161426850 @default.
- W4200327520 cites W2166846975 @default.
- W4200327520 cites W2173764926 @default.
- W4200327520 cites W2235405584 @default.
- W4200327520 cites W2530131158 @default.
- W4200327520 cites W2585697071 @default.
- W4200327520 cites W2598264809 @default.
- W4200327520 cites W2618058692 @default.
- W4200327520 cites W2737389832 @default.
- W4200327520 cites W2754327139 @default.
- W4200327520 cites W2774580734 @default.
- W4200327520 cites W2897430921 @default.
- W4200327520 cites W2947158665 @default.
- W4200327520 cites W2947826965 @default.
- W4200327520 cites W2975141952 @default.
- W4200327520 cites W2989861603 @default.
- W4200327520 cites W2989894179 @default.
- W4200327520 cites W3004461112 @default.
- W4200327520 cites W3005738019 @default.
- W4200327520 cites W3006930853 @default.
- W4200327520 cites W3025029989 @default.
- W4200327520 cites W3041271367 @default.
- W4200327520 cites W3047097799 @default.
- W4200327520 cites W3089446304 @default.
- W4200327520 cites W3095107109 @default.
- W4200327520 cites W3106261235 @default.
- W4200327520 cites W3165576985 @default.
- W4200327520 cites W3168935284 @default.
- W4200327520 cites W3172346887 @default.
- W4200327520 cites W3185612921 @default.
- W4200327520 doi "https://doi.org/10.1200/jco.21.01657" @default.
- W4200327520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34910554" @default.
- W4200327520 hasPublicationYear "2022" @default.
- W4200327520 type Work @default.
- W4200327520 citedByCount "21" @default.
- W4200327520 countsByYear W42003275202021 @default.
- W4200327520 countsByYear W42003275202022 @default.
- W4200327520 countsByYear W42003275202023 @default.
- W4200327520 crossrefType "journal-article" @default.
- W4200327520 hasAuthorship W4200327520A5000862048 @default.
- W4200327520 hasAuthorship W4200327520A5002316061 @default.
- W4200327520 hasAuthorship W4200327520A5003348942 @default.
- W4200327520 hasAuthorship W4200327520A5005007467 @default.
- W4200327520 hasAuthorship W4200327520A5006346528 @default.
- W4200327520 hasAuthorship W4200327520A5009816526 @default.
- W4200327520 hasAuthorship W4200327520A5010925062 @default.
- W4200327520 hasAuthorship W4200327520A5015980183 @default.
- W4200327520 hasAuthorship W4200327520A5018790034 @default.
- W4200327520 hasAuthorship W4200327520A5018890673 @default.
- W4200327520 hasAuthorship W4200327520A5020251022 @default.
- W4200327520 hasAuthorship W4200327520A5029357210 @default.
- W4200327520 hasAuthorship W4200327520A5032268177 @default.
- W4200327520 hasAuthorship W4200327520A5033046698 @default.